The monitoring of DEA-controlled substances for suspicious orders is widely recognized. Companies have an obligation not only to implement a system for identifying unusual-sized, frequent, and patterned orders of DEA-controlled substances but also to apply similar measures to monitor other product categories (such as State Controlled, High Potential for Diversion, and Rx).

Key Topics:

• Overview of monitoring products that are controlled at the state level
• Insights on monitoring products that have a high potential for diversion
• Discussion of monitoring products that are non-controls (Rx products)

Speakers:

Eric Pearcy
Engagement Manager, IQVIA

Scott Hardy
Sr. Engagement Manager, IQVIA